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A B S T R A C T
Background: Kpa antigen is a low incidence red blood cell antigen within the Kell system.
Anti-Kpa alloantibody may be associated with acute and delayed hemolytic transfusion
reactions.
Case Study: We report a case of a clinically signiﬁcant acute extravascular hemolytic trans-
fusion reactionmediated by previously unrecognized (and undetected) anti-Kpa alloantibody.
This reaction occurred in a patient who met all criteria for electronic crossmatch,
resulting in the transfusion of an incompatible red cell unit.
Results: Post-transfusion investigation showed the transfused red cell unit was crossmatch
compatible at the immediate spin phase but was 3 + incompatible at the antiglobulin phase.
No evidence of intravascular hemolysis was observed upon visual comparison of the pre-
and post-transfusion peripheral blood plasma. Further testing showed the presence of anti-
Kpa antibody. The clinical course of the patient included acute febrile and systemic reaction.
Conclusion: Acute extravascular hemolytic transfusion reaction may occur due to unde-
tected anti-Kpa alloantibody. Various strategies for crossmatching are discussed in the context
of antibodies to low incidence antigens.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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1. Introduction
The Kpa antigen (KEL3, Penney) is a low incidence red
blood cell antigen within the Kell system. Only approxi-
mately 2% of blood donors are Kpa positive [1]. Antibodies
against antigens within the Kell system are usually IgG type
and acquired through exposure to antigen positive red
blood cells during pregnancy or transfusion, although the
antibody may occasionally be naturally occurring, as was
the case in the original description of this antibody [2].
Anti-Kpa alloantibody is known to be clinically signiﬁcant
and associated with both acute and delayed hemolytic
transfusion reactions as well as hemolytic disease of the fetus
and newborn (HDFN) [2–4]. Given the rarity of the Kpa
antigen, antibodies to this antigen are not common.
Computer-assisted electronic crossmatching is stan-
dard practice in many transfusion laboratories if speciﬁc
requirements are met [5]. The recipient must not have any
evidence of clinically signiﬁcant antibodies, presently or in
the past. At least two concordant results of ABO and RhD
typing must be on record, including one from the current
sample. Additional laboratory information system require-
ments must also be met. When electronic crossmatching is
performed neither an immediate spin nor antiglobulin phase
crossmatch between recipient plasma and donor red cells
is required. Electronic crossmatch has cost–beneﬁts and is
safe for most patients. However, it is known that potential-
ly clinically signiﬁcant antibodies, including antibodies to
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low incidence antigens may be missed by electronic
crossmatch [6].
We report here a case of a clinically signiﬁcant acute ex-
travascular hemolytic transfusion reaction mediated by
previously unrecognized (and undetected) anti-Kpa anti-
body in a patient who met all criteria for electronic
crossmatch, resulting in the transfusion of an incompatible
red cell unit.
2. Case report
A 64 year old clinically obese female with diabetes and
previous history of myocardial infarction was admitted for
urgent repair of a hiatal hernia. The patient had two pre-
vious pregnancies. The patient had remote history of
transfusion in the 1980s through which she acquired hep-
atitis C. The patient had a more recent history of red cell
transfusion with one unit of red cells transfused after gas-
trointestinal bleeding 5 years earlier at which time no
antibodies were identiﬁed.
The patient was blood group O, RhD positive. At the time
of current presentation, the antibody screen was negative.
The hemoglobin was 82 g/L pre-transfusion. One unit of
group O, RhD positive, leukoreduced packed red blood cell
(PRBC) unit was issued to the patient after electronic
crossmatch indicated compatibility. During the transfu-
sion, the patient experienced an elevation in temperature,
from 37.9 °C pre-transfusion to 39.5 °C during transfusion,
accompanied by chills/rigors, and soon followed by short-
ness of breath. The transfusion was permanently
discontinued. At this point the patient had received about
200 mL of PRBCs.
Immediately after the transfusion the hemoglobin was
90 g/L. The patient was given supplemental oxygen, bron-
chodilator (salbutamol) and bilevel positive airway pressure
(BPAP) ventilatory support for a few hours. The patient’s
signs and symptoms resolved within a few hours with no
additional intervention. Patient blood cultures and cul-
tures of the remainder of the PRBC unit were negative.
Transient elevation of the total bilirubin and lactate dehy-
drogenase was noted (Fig. 1). Transient elevation of troponin
I was observed following the incompatible red cell trans-
fusion, peaking just before the surgery (Fig. 2). EKG
performed before the incompatible red cell transfusion
showed old anterior myocardial infarct. EKG performed after
the surgery showed atrial ﬁbrillation and evidence of new
inferior wall ischemia. No EKG was performed in the inter-
val after the incompatible red cell transfusion and before
the surgery. One day after receiving the incompatible PRCB
unit, the patient underwent laparoscopic reduction of the
hiatal hernia and gastrostomy tube insertion without
incident.
On post-operative day 2 the hemoglobin was noted to
be 83 g/L. Two Kpa-negative PRBC units were found to be
compatible with the patient’s plasma at the anti-globulin
phase crossmatch. One unit was transfused with no reac-
tion. The patient was discharged from hospital one week
after surgery in stable condition.
3. Materials and methods
For all transfusion testing, an appropriately identiﬁed
EDTA tube of peripheral blood was obtained from the
patient. ABO and RhD typing was performed using
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Fig. 1. Laboratory values from the day before to 8 days following transfusion of incompatible red cell unit. Black arrow indicates when incompatible
transfusion occurred. (Hgb = hemoglobin g/L, LD = lactate dehydrogenase U/L, T-bil = total bilirubin umol/L).
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microplate technology on the Galileo Neo instrument
(Immucor Inc. Norcross, GA, USA). A three cell antibody
screen was performed by solid phase technology using the
CAPTURE-R READY-SCREEN (3), Lot No. R311 (Immucor Inc,
Norcross). A red cell unit was assigned to the patient using
the electronic crossmatch validated to be compliant with
published standards [7].
Laboratory testing for the investigation of the reported
transfusion reaction was performed in keeping with stan-
dard methodologies [5]. An immediate spin crossmatch was
performed by adding two drops of patient post-transfusion
plasma to an empty tube with one drop of 3% red cell sus-
pension prepared from the implicated donor red cell unit
segment. After mixing, the tubewas centrifuged at 3400 rpm
for 15 seconds. The solution was examined for hemolysis.
The red cell button was resuspended and read macroscopi-
cally for agglutination. As no agglutination or hemolysis was
observed the test was reported as negative.
The test was continued to the antiglobulin phase by
adding two drops PEG reagent to the tube and incubating
at 37 °C for 15minutes. The solution was washed four times.
Two drops of anti-IgG were added, gently mixed and then
centrifuged at 3400 rpm for 15 seconds. Immediately after
centrifugation the cells were resuspended and read mac-
roscopically. The antiglobulin crossmatch was incompatible
with grade 3 agglutination.
A direct antiglobulin test (DAT) was performed by
washing one drop of the patient 3% red cell suspension to
a dry cell button and then adding two drops of polyspeciﬁc
antihuman globulin reagent. After mixing the tube was cen-
trifuged at 3400 rpm for 15 seconds. Immediately after
centrifugation the cells were resuspended and examined
both macroscopically and microscopically. The polyspeciﬁc
DAT was reported as weakly positive (microscopic). Differ-
ential DAT testing was performed by the same technique
using monospeciﬁc reagents. The anti-IgG showed a weakly
positive result and anti-C3 was weakly positive only after
5 minute room temperature incubation.
4. Results
Prior to the ﬁrst (incompatible) PRBC transfusion the
patient was typed as group O, Rh positive, consistent with
the patient’s historical blood group on ﬁle. No history of pre-
existing antibodies was known and the pre-transfusion
antibody screen was negative using a three-cell panel. One
unit of PRBCs was selected using electronic crossmatch
and was visually inspected to conﬁrm suitability for
transfusion.
Following the febrile transfusion reaction, a clerical check
was performed, and no errors were found, with the name
and identiﬁcation numbers and donor unit numbers
and labels identical on all specimens and request forms. The
pre- and post-transfusion peripheral blood specimens were
visually inspected for hemolysis, and no evidence of he-
molysis in the plasma was observed (Fig. 3). The post-
transfusion crossmatch was compatible at the immediate
spin phase, but was 3 + incompatible at the antiglobulin
phase. DAT testing was performed on the pre-transfusion
sample and found to be negative. However, DAT on a post-
transfusion sample was weakly positive for anti-IgG. The
anti-C3 DAT was negative at time = 0, but then found to be
weakly positive after 5 minutes of incubation at room tem-
perature. The transfused red cell unit was typed as Kpa
positive. The patient’s pre-transfusion red cells were
phenotyped and shown to be Kpa negative. Extended
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Fig. 2. Troponin I results from the day before to 3 days following transfusion of incompatible red cell unit. Black arrow indicates when incompatible
transfusion occurred. Note that the peak Troponin I level of 2.49 μg/L was observed before the surgery for hiatal hernia repair.
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antibody investigation using the post-transfusion plasma
sample showed 3 + positive reaction with Kpa positive cells.
No other red cell antibodies were identiﬁed.
5. Discussion
Kpa is a low frequency antigen of the Kell system [1]. An-
tibodies to Kpa usually develop following transfusion or
through fetal-maternal immunization, but may be natural-
ly occurring [1]. Delayed hemolytic transfusion reaction and
hemolytic disease of the fetus or newborn due to anti-Kpa
are usually only mild to moderate; however one case of
severe delayed hemolytic transfusion reaction has been
reported [3].
The risk of acute hemolytic transfusion reaction due to
missed antibody to low frequency antigen has been esti-
mated at 1 per 650,000 crossmatches using immediate spin
or electronic crossmatch technology [8]. Two recent studies
have identiﬁed anti-Kpa in 3% and 4.7% of patients requir-
ing chronic transfusion therapy who have alloantibodies to
red cells [9,10]. Kpa antigen is present in approximately 2%
of Caucasians [1]. If this antigen frequency if multiplied by
the antibody frequency listed above, it can be calculated that
incompatibility will be encountered in up to 0.094% or ap-
proximately 1 in 1000 transfusions in this population.
However, it should be noted, that since allo-immunized pa-
tients are not eligible for electronic or immediate spin
crossmatching, anti-Kpa antibody is unlikely to be missed
in this population.
Electronic crossmatch is a safe and effective method for
selection of red cells for transfusion, and carries a similar
risk of missing low incidence antibodies as immediate spin
crossmatch techniques. As such antibodies generally do not
cause severe hemolytic transfusion reactions this risk is
readily accepted by most transfusion services [6]. However
acute extravascular hemolytic transfusion reaction may be
associated with fever due to acute cytokine release [11], and
may stress an already vulnerable patient, as in this case
report, where the patient had signiﬁcant co-morbidities, and
exhibited a transient elevation of troponin I following
transfusion of the incompatible red cell unit.
An option to ensure that the transfusion service avoids
missing antibodies to low incidence antigens may be to
include testing red cells with low incidence antigens in pre-
transfusion antibody screening. This may be an approach
suitable for reference transfusion medicine laboratories and
suggested antigens may include Vel, Jsa, Deigo, Cw,Wra and
Kpa. This has the advantage of avoiding acute hemolytic
transfusion reactions due to missed alloantibodies, but has
the disadvantage of added time and expense. In an ideal
world, transfusion requisitions would contain a wealth of
relevant clinical information to enable laboratories to select
appropriate patients in whom to perform this extended
testing. Computer provider order entry (CPOE) may be a tool
that will enable this and it is important for transfusion spe-
cialists to advocate for technologies that will allow the safest,
yet most ﬁscally responsible testing algorithms in their hos-
pitals [12]. Until such utopian visions for transfusion testing
and therapy are achieved, it is important to report cases such
as these that may assist others in timely identiﬁcation and
management of similar transfusion reactions, and enable re-
ﬂection on the various strategies for antibody identiﬁcation
and crossmatching policies and procedures and their impact
on patient care.
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Fig. 3. (A) Pre-transfusion plasma. (B) Post-transfusion plasma. No
hemolysis noted.
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